QIHAN BIOTECH

Home About Us Science Newsroom Careers Contact

Press Releases

Qihan Biotech Announces Multiple Presentations at the 2025 American Society of Hematology (ASH) Annual Meeting Learn More

Qihan Biotech Announces FDA Clearance of IND for QT-019B, a Universal Dual-Target CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus Learn More

Qihan Biotech Appoints Tony W. Ho to its Board of Directors Learn More

iPSC-CAR-NK Cell Therapy Clinical Results Published in Cell, Marking a Global Breakthrough in Autoimmune Disease Treatment Learn More

Qihan Biotech Announces Multiple Presentations at the 2025 American Society of Hematology (ASH) Annual Meeting

At the upcoming 2025 ASH Annual Meeting, Qihan Biotech will present new data highlighting significant progress across its off-the-shelf and in vivo CAR-T cell therapy programs.

Qihan Biotech Announces FDA Clearance of IND for QT-019B, a Universal Dual-Target CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus

The U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for QT-019B.

iPSC-CAR-NK Cell Therapy Clinical Results Published in Cell, Marking a Global Breakthrough in Autoimmune Disease Treatment

Qihan Biotech announced the publication of groundbreaking clinical results in Cell.

Qihan Biotech Presented its Breakthrough CAR-T Research at ASGCT 2025

QihanBiotech announced new advancements in its universal CAR-T cell therapy research, to be presented at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).

Qihan Biotech Announces Appointment of Carl June to Scientific Advisory Board

Qihan Biotech is proud to announce the appointment of Dr. Carl June as Cell Therapy Chair of its Scientific Advisory Board.

Qihan Biotech Announces Publication in Microbiology Spectrum of CRISPR-Cas Multiplexed Genome Editing for Reducing African Swine Fever Virus

Qihan Biotech announced its groundbreaking research titled "Testing Multiplexed anti-ASFV CRISPR-Cas9 in Reducing African Swine Fever Virus" in Microbiology Spectrum, an academic journal of the American Society for Microbiology.

Qihan Biotech Appoints Yingyong Xu to its Chief Medical Officer

Qihan Biotech today announced the appointment of Mr. Yingyong Xu as the Chief Medical Officer.

Qihan Biotech Appoints Naxin Yao to its Board of Directors

Qihan Biotech today announced the appointment of Mr. Naxin Yao to its Board of Directors as an independent director.

Qihan Biotech Announces NMPA Approval of Investigational New Drug (IND) Application for QN-019a, a Multi-locus Gene-Editing Cell Therapy Product to treat CD19-positive B-Cell Lymphoma

Qihan Biotech announced today that the National Medical Products Administration (NMPA) approved its clinical trial application for the product QN-019a.